Rapid Reviews COVID-19

Reviews of "Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial"

Ying-Rong Du¹, Hai-yan Fu¹, Ariel Berlinski²

¹Dali University, sixth affiliated hospital, China,

²Professor, University of Arkansas for Medical Sciences, Pediatrics

Published on: Apr 26, 2021

DOI: 10.1162/2e3983f5.3790e6f9

License: [Creative Commons Attribution 4.0 International License \(CC-BY 4.0\)](https://creativecommons.org/licenses/by/4.0/)

To read the original manuscript, click the link above.

Summary of Reviews: This study suggests that budesonide, a corticosteroid used for COPD and asthma treatment, reduces the likelihood of urgent care, ED visit, or hospitalization in patients with early COVID-19; both reviewers found the study findings to be reasonable and potentially reliable.

Reviewer 1 (Ying-Rong Du, Hai-yan Fu) |

Reviewer 2 (Ariel Berlinski) |

RR:C19 Strength of [Evidence Scale Key](#)

= Misleading

= Not Informative

= Potentially Informative

= Reliable

= Strong

To read the reviews, click the links below.